Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Slightly off-topic; Folotyn is a damn expensive drug! When I saw an article today under Spectrum related articles titled "The 5 Most Expensive Drugs In US: What You Should Know" I was puzzled on what that has to do w Spectrum. Per the article

4. Folotyn

Folotyn, which is now under the stable of Aurobindo Pharma USA Inc's subsidiary Acrotech Biopharma, is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

It was approved by the FDA in September 2009.

Folotyn was originally developed by Allos Therapeutics, which was acquired by Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) in 2012. Recently, Spectrum sold the drug to Acrotech.

The drug costs $745,785 annually.

Yikes! So when I used $200,000 as the price for the annual cost of pozi, well, relatively, that's not as expensive as it appears.

Per Spectrum’s Presentation, there are 7700 NSCLC EGFR and HER2 combined patients who could take pozi. Fifty-eight % of those have the NSCLC EGFR exon 20 mutation (cohort 1 in the Zenith 20 trial) or ~5000 patients. At $200,000 per treatment (Loxo's Vitrakvi is $400,000/year), that’s $1B.